Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 12:12:655054.
doi: 10.3389/fphar.2021.655054. eCollection 2021.

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective

Carsten Schmidt  1 , Philip C Grunert  2 , Andreas Stallmach  2
Affiliations
Review

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective

Carsten Schmidt et al. Front Pharmacol. .

Abstract

The introduction of anti-tumor necrosis factor antibodies resulted in a considerable expansion of the options available for the treatment of inflammatory bowel disease. Unfortunately, approximately one third of treated patients do not respond to these modalities, and drug efficacy may be lost over time. These drugs are also associated with contraindications, adverse events, and intolerance. As such, there is an ongoing need for new therapeutic strategies. Despite several recent advances, including antibodies against pro-inflammatory cytokines and cell adhesion molecules, Janus kinase inhibitors, and modulators of sphingosine-1-phosphate receptors, not all problems associated with IBD have been solved. In this manuscript, we review the current state of development of several new treatment options. Ongoing evaluation will require specific proof of efficacy as well as direct comparisons with established treatments. Results from head-to-head comparisons are needed to provide clinicians with critical information on how to formulate effective therapeutic approaches for each patient.

Keywords: JAK inhibitor; anti-integrin drugs; biologics; fecal microbiota transplantation; interleukin-23; small molecule; sphingosine-1-phosphate receptor modulator.

PubMed Disclaimer

Conflict of interest statement

CS obtained consulting fees from Abbvie, Biogen, Ewopharma, Janssen, MSD, Pfizer, and Takeda, lecture fees and travel support from Abbvie, Berlin Chemie, Biogen, Ewopharma, Falk, Janssen, Merckle, MSD, Norgine, Novartis, Pfizer, Shire, Shield Therapeutics, and Takeda, and research support from Abbvie. PCG obtained consulting fees from Janssen and Takeda and lecture fees and travel support from AbbVie, Janssen, Pfizer, and Takeda. AS obtained consulting fees from Abbvie, Amgen, Astellas, Biogen, Celltrion, Consal, CSL Behring, Galapagos, Gilead, Institut Allergosan, Janssen, MSD, Norgine, Pfizer Pharma, Roche, Shire, Summit Therapeutics, and Takeda, lecture fees and travel support from Abbvie, Astellas, Celltrion, Falk Foundation, Ferring, Janssen, MSD, Recordati Pharma, and Takeda, and research support from Abbvie. The reviewer JZ declared a past co-authorship with one of the authors AS to the handling editor.

Figures

FIGURE 1
FIGURE 1
Mechanisms of action of several of the new therapeutic agents used to treat IBD.
See this image and copyright information in PMC

References

    1. Coward S., Clement F., Benchimol E. I., Bernstein C. N., Avina-Zubieta J. A., Bitton A., et al. (2019). Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156 (5), 1345–1353. 10.1053/j.gastro.2019.01.002 e1344 - DOI - PubMed
    1. Danese S., Feagan B. G., Wolf D. C., Hanauer S. B., Jovanovic I., Ghosh S., et al. (2020a). “Ozanimod as maintenance therapy in patients with moderate-to-severe ulcerative colitis: results from the phase 3, randomized, double-blind,” in Placebo-controlled true north study (Vienna, Austria: United European Gastroenterology Week; ), LB10.
    1. Danese S., Neurath M. F., Kopoń A., Zakko S. F., Simmons T. C., Fogel R., et al. (2020b). Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin. Gastroenterol. Hepatol. 18 (11), 2526–2534. 10.1016/j.cgh.2019.12.032 - DOI - PubMed
    1. Danese S., Sandborn W. J., Reinisch W., Hébuterne X., Kłopocka M., Tarabar D., et al. (2019). Long-term mucosal healing, clinical response and clinical remission in patients with ulcerative colitis treated with the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody ontamalimab (SHP647): results from the open-label extension study TURANDOT II. United European Gastroenterol. J. 7 (8 Suppl. l), 84. 10.14309/01.ajg.0000592624.44779.ee - DOI
    1. Dotan I. P. J., Duvall A., Bouhnik Y., Radford-Smith G., Higgins P. D. R., Mishkin D. S., et al. (2020). Etrolizumab compared with adalimumab or placebo as induction therapy for ulcerative colitis: results from the randomized, phase 3 Hibiscus I & ii trials, LB09. Vienna, Austria: United European Gastroenterology Week.